C-QWVDmedicines, vaccines, clinical trials
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Determine whether adding zanzalintinib to belzutifan helps people with advanced renal cell carcinoma live longer overall and without cancer progression compared with belzutifan alone.
Clinical study comparing belzutifan plus zanzalintinib versus belzutifan plus placebo.
ClinicalTrials.gov record published for NCT07489495 on 2026-04-09.
Evaluate whether nemtabrutinib improves progression-free survival versus standard chemoimmunotherapy in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without TP53 aberrations.
Clinical study comparing nemtabrutinib with standard treatments.
ClinicalTrials.gov record published for NCT05624554 on 2023-03-16.
Test whether lenvatinib plus pembrolizumab improves overall survival versus standard chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma after platinum therapy and immunotherapy.
Clinical trial comparing lenvatinib plus pembrolizumab, standard chemotherapy, and lenvatinib monotherapy.
ClinicalTrials.gov record published for NCT04428151 on 2020-08-06.
Assess real-world effectiveness and safety of cladribine tablets in multiple sclerosis participants switching from first-line disease-modifying drugs.
Prospective real-world effectiveness and safety study measuring annualized relapse rate and disability progression.
ClinicalTrials.gov record published for NCT04934800 on 2019-12-10.
Evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of intratumoral or intralesional MK-4621 alone or with pembrolizumab in advanced, metastatic, or recurrent solid tumors.
Intratumoral/intralesional MK-4621 delivered via JetPEI nucleic acid delivery system, as monotherapy or in combination with pembrolizumab.
ClinicalTrials.gov record published for NCT03739138 on 2018-12-18.
Evaluate safety of two doses of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Clinical study of gefapixant MK-7264 dose regimens.
ClinicalTrials.gov record published for NCT03696108 on 2018-10-31.
Explore safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple ascending doses of anti-ADAMTS-5 nanobody in symptomatic knee osteoarthritis.
Multiple ascending dose clinical study of M6495 in knee osteoarthritis participants.
ClinicalTrials.gov record published for NCT03583346 on 2018-08-23.
Treat previously untreated locally advanced or metastatic urothelial carcinoma and improve response, progression-free survival, and overall survival.
Combination therapy with enfortumab vedotin 1.25 mg/kg on days 1 and 8 plus pembrolizumab 200 mg on day 1 of each 3-week cycle; phase Ib/II follow-up and supporting phase 3 evidence.
5-year follow-up from EV-103/KEYNOTE-869 reported in 2026, supporting the combination as standard of care alongside EV-302/KEYNOTE-A39.
In 45 patients, confirmed ORR was 73.3%, median DOR was 22.1 months, median PFS was 12.7 months, median OS was 26.1 months, and estimated 5-year survival was 41.5%; no new safety signals were observed.
Treat non-microsatellite instability-high/mismatch repair proficient advanced or recurrent endometrial cancer after prior systemic therapy.
Combination therapy with lenvatinib plus pembrolizumab compared with chemotherapy in trial evidence and real-world retrospective medical record analysis.
2026 real-world analysis confirmed clinical benefit versus single-agent chemotherapy in second-line or later use.
Real-world objective response rate was 41.6% versus 28.2% for chemotherapy; median progression-free survival was 13.1 versus 8.4 months; median overall survival was 19.6 versus 13.5 months.
Support drug discovery by estimating compound binding affinity changes at industrial scale using reproducible open-source relative binding free energy calculations.
Open-source MIT-licensed alchemical free energy/RBFE protocol benchmarked by 15 pharmaceutical companies across public and blinded private ligand datasets.
2026 large-scale collaborative assessment across more than 1,700 ligands reported performance suitable for large-scale industrial applications.
Weighted RMSE was 1.73 kcal/mol across 58 public systems and 2.44 kcal/mol across 37 private systems; performance was system-dependent but robust and reproducible.
Evaluate pembrolizumab treatment in participants with relapsed or refractory classical Hodgkin lymphoma compared with brentuximab vedotin.
Randomized clinical study of pembrolizumab for up to 35 three-week cycles versus brentuximab vedotin.
ClinicalTrials.gov record included in supplied public records.